Diagnosis of multiple myeloma as defined by IMWG criteria
Measurable disease based on IMWG criteria
Received 2-4 prior lines of therapy (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader)
Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
Participants with any active, uncontrolled bacterial, fungal, or viral infection
Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy
Administration with an investigational product within 30 days preceding the first dose of study intervention
Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
Clareo Health | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
